Dr. Seung Tae Lee
Claim this profileUniversity of Maryland Greenebaum Comprehensive Cancer Center
Studies Lymphoma
Studies Leukemia
4 reported clinical trials
14 drugs studied
Area of expertise
1Lymphoma
Stage I
Stage II
Stage III
2Leukemia
Stage I
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Seung Tae Lee is currently running
CC-99282 + Anti-Lymphoma Agents
for Non-Hodgkin's Lymphoma
This trial is testing a new drug, CC-99282, for patients with certain types of lymphoma who haven't responded to other treatments. Researchers are finding the safest dose and checking if it works better alone or with other drugs.
Recruiting1 award Phase 1 & 22 criteria
Selinexor + R-GDP
for Lymphoma
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), followed by 60 mg selinexor single agent continuous therapy for those who have reached a partial or complete response. Phase 3 portion of the study will evaluate the selected dose of SR-GDP (identified in Phase 2) versus standard R-GDP + matching placebo, for up to 6 cycles (21-day per cycle), followed by placebo or 60 mg selinexor single agent continuous therapy for those who have reached partial or complete response.
Recruiting0 awards Phase 2 & 39 criteria
More about Seung Tae Lee
Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Seung Tae Lee has experience with
- Obinutuzumab
- Rituximab
- AS-1763
- Venetoclax
- Ibrutinib
- CC-99282
Breakdown of trials Seung Tae Lee has run
Lymphoma
Leukemia
Non-Hodgkin's Lymphoma
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Seung Tae Lee specialize in?
Seung Tae Lee focuses on Lymphoma and Leukemia. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage II.
Is Seung Tae Lee currently recruiting for clinical trials?
Yes, Seung Tae Lee is currently recruiting for 3 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Seung Tae Lee has studied deeply?
Yes, Seung Tae Lee has studied treatments such as Obinutuzumab, Rituximab, AS-1763.
What is the best way to schedule an appointment with Seung Tae Lee?
Apply for one of the trials that Seung Tae Lee is conducting.
What is the office address of Seung Tae Lee?
The office of Seung Tae Lee is located at: University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland 21201 United States. This is the address for their practice at the University of Maryland Greenebaum Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.